1. Home
  2. AVDL vs RBBN Comparison

AVDL vs RBBN Comparison

Compare AVDL & RBBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • RBBN
  • Stock Information
  • Founded
  • AVDL 2015
  • RBBN 1997
  • Country
  • AVDL Ireland
  • RBBN United States
  • Employees
  • AVDL N/A
  • RBBN N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • RBBN EDP Services
  • Sector
  • AVDL Health Care
  • RBBN Technology
  • Exchange
  • AVDL Nasdaq
  • RBBN Nasdaq
  • Market Cap
  • AVDL 784.6M
  • RBBN 662.0M
  • IPO Year
  • AVDL 1996
  • RBBN 2000
  • Fundamental
  • Price
  • AVDL $9.11
  • RBBN $3.38
  • Analyst Decision
  • AVDL Strong Buy
  • RBBN Strong Buy
  • Analyst Count
  • AVDL 6
  • RBBN 4
  • Target Price
  • AVDL $18.17
  • RBBN $5.88
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • RBBN 449.8K
  • Earning Date
  • AVDL 05-07-2025
  • RBBN 07-23-2025
  • Dividend Yield
  • AVDL N/A
  • RBBN N/A
  • EPS Growth
  • AVDL N/A
  • RBBN N/A
  • EPS
  • AVDL N/A
  • RBBN N/A
  • Revenue
  • AVDL $194,450,000.00
  • RBBN $835,496,000.00
  • Revenue This Year
  • AVDL $55.11
  • RBBN $7.27
  • Revenue Next Year
  • AVDL $30.13
  • RBBN $5.32
  • P/E Ratio
  • AVDL N/A
  • RBBN N/A
  • Revenue Growth
  • AVDL 252.64
  • RBBN 1.91
  • 52 Week Low
  • AVDL $6.38
  • RBBN $2.75
  • 52 Week High
  • AVDL $17.30
  • RBBN $5.38
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 53.96
  • RBBN 43.21
  • Support Level
  • AVDL $8.77
  • RBBN $3.50
  • Resistance Level
  • AVDL $9.31
  • RBBN $3.66
  • Average True Range (ATR)
  • AVDL 0.41
  • RBBN 0.14
  • MACD
  • AVDL -0.04
  • RBBN 0.00
  • Stochastic Oscillator
  • AVDL 53.60
  • RBBN 25.00

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About RBBN Ribbon Communications Inc.

Ribbon Communications Inc provides network solutions to service providers and enterprises. The company enables service providers and enterprises to modernize their communications networks and provide secure real-time communications solutions to their customers and employees. The company has two separate lines of business; the Cloud and Edge segment, and the IP Optical Networks segment. The majority of the revenue for the company is generated from its Cloud and Edge segment that provides secure and reliable software and hardware products, solutions, and services for VoIP communications, Voice Over LTE among others to service providers and enterprise customers. The company generates majority of its revenue from United States.

Share on Social Networks: